Form 4: Arcutis Biotherapeutics CEO Sells Shares to Cover Tax Obligations

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 13,871 shares of common stock on November 4, 2024, to cover tax obligations related to the vesting of Restricted Stock Units.

Summary

• On November 4, 2024, Todd Franklin Watanabe, the CEO of Arcutis Biotherapeutics, sold 13,871 shares of the company's common stock.
• The sale was executed at a weighted average price of $8.6842 per share, with individual transactions ranging from $8.32 to $8.86.
• The purpose of the sale was to satisfy tax withholding obligations associated with the vesting of Watanabe's Restricted Stock Units (RSUs).
• Following the transaction, Watanabe directly owns 832,392 shares of Arcutis Biotherapeutics.
• Watanabe also has indirect ownership through several trusts and an LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

Sales of shares to cover tax obligations are a common practice among executives receiving equity compensation. This transaction is a routine event and doesn't necessarily indicate a change in the executive's confidence in the company.

Key Dates